Nilai Buku saben Saham: Genetic Technologies (GENE)

Genetic Technologies is expanding its B2B presence by implementing comprehensive geneType IT tests in clinics. The company aims to establish predictive genetics as a standard for cancer and cardiac pathology prevention through PRS analyses. The book value per share reflects net asset dynamics, where the parameter mark equals 0.27. Prospects depend on integration into US insurance plans and new FDA requirements for LDT tests.

GTG Labs (GENE) - Nilai Akuntansi saben Saham saka 04.07.2022 nganti 26.10.2024

Ringkesan rincian data analitis Genetic Technologies Ltd (GENE)

- rega lan prakiraan konsensus rega:

Bagan rega GTG Labs|GENE - Prakiraan gabungan firma investasi

- data kapitalisasi pasar:

Kapitalisasi pasar Genetic Technologies Limited|GENE - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Genetic Technologies|GENE - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku gtglabs.com|GENE - Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Genetic Technologies|GENE - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal GTG Labs|GENE - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Genetic Technologies Limited

Pambiji fundamental perusahaan:Genetic Technologies

Produk asil prodhuksi Genetic Technologies Ltd

Book value per share reflects the portion of net equity attributable to a single security, serving as an internal indicator of asset value minus liabilities. By analyzing the reference book value per share of Genetic Technologies (GENE), an investor can assess the company's margin of safety amid constrained pricing power caused by insurance company pressure, which determines the real value of the business under conditions of low operating margins.

Pesaing Genetic Technologies (GENE)